Obalon Therapeutics, Inc.
OBLN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -97.2% | 11.6% | -86% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 52.1% | 48.2% | 61.2% | 62.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -24,740.5% | -170.6% | -165.2% | -23.2% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -24,822.5% | -211.8% | 132.4% | -20.6% |
| EPS Diluted | 0 | -2.25 | 18.98 | -13.22 |
| % Growth | 100% | -111.9% | 243.6% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |